Royce & Associates’s Maravai LifeSciences MRVI Stock Holding History

Royce & Associates’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.3M	Hold	1,808,448	–	–	0.09%	350
2026 Q1	$5.12M	Buy	1,808,448 +102,299	+6%	+$347K	0.05%	461
2025 Q4	$5.54M	Sell	1,706,149 -55,615	-3%	-$187K	0.06%	446
2025 Q3	$5.06M	Buy	1,761,764 +484,908	+38%	+$1.24M	0.05%	467
2025 Q2	$3.08M	Sell	1,276,856 -51,588	-4%	-$108K	0.03%	544
2025 Q1	$2.94M	Buy	1,328,444 +369,559	+39%	+$1.46M	0.03%	529
2024 Q4	$5.23M	Buy	958,885 +50,107	+6%	+$322K	0.05%	467
2024 Q3	$7.55M	Buy	908,778 +514,332	+130%	+$4.45M	0.07%	388
2024 Q2	$2.82M	Buy	394,446 +378,009	+2,300%	+$3.26M	0.03%	579
2024 Q1	$143K	Buy	+16,437	New	+$111K	﹤0.01%	844
2023 Q1	–	Sell	-54,106	Closed	-$774K	–	936
2022 Q4	$774K	Buy	+54,106	New	+$852K	0.01%	784
2022 Q3	–	Sell	-458,788	Closed	-$13M	–	956
2022 Q2	$13M	Buy	458,788 +109,303	+31%	+$3.46M	0.13%	224
2022 Q1	$12.3M	Buy	+349,485	New	+$11.7M	0.1%	293

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Royce & Associates's MRVI Position: Q2 2026 in Review

Royce & Associates held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 1,808,448 shares worth $11.3M. The position accounts for 0.09% of the portfolio, ranked #350.

Royce & Associates first reported a position in MRVI in Q1 2022 and has held it in 13 quarters since. The position peaked at $13M in Q2 2022. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Royce & Associates held 1,808,448 shares of Maravai LifeSciences worth $11.3M as of Q2 2026.
Royce & Associates left its Maravai LifeSciences share count unchanged in Q2 2026.
Maravai LifeSciences made up 0.09% of Royce & Associates's portfolio in Q2 2026, its #350 holding.
Royce & Associates first reported a position in Maravai LifeSciences in Q1 2022 and has held it in 13 quarters since.
Royce & Associates's Maravai LifeSciences position peaked at $13M in Q2 2022.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.